TrivarX Limited (ASX:TRI)
Australia · Delayed Price · Currency is AUD 0.0310
+0.0010 (3.33%)
Feb 12, 2026, 4:10 PM AEST
TrivarX Revenue
In the fiscal year ending June 30, 2025, TrivarX had annual revenue of 1.03M AUD with 16.00% growth. TrivarX had revenue of -97.63K in the half year ending June 30, 2025.
Revenue
1.03M
Revenue Growth
+16.00%
P/S Ratio
33.57
Revenue / Employee
171.85K
Employees
6
Market Cap
34.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.03M | 142.24K | 16.00% |
| Jun 30, 2024 | 888.83K | -71.62K | -7.46% |
| Jun 30, 2023 | 960.45K | -45.00K | -4.48% |
| Jun 30, 2022 | 1.01M | -258.10K | -20.43% |
| Jun 30, 2021 | 1.26M | 338.28K | 36.56% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adheris Health | 62.99M |
| Beamtree Holdings | 28.60M |
| ImExHS | 26.32M |
| Resonance Health | 11.07M |
| PharmX Technologies | 7.53M |
| Vitasora Health | 3.71M |
| PainChek | 3.36M |
| Emyria | 1.39M |